Pfizer Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
- Cancellation by sponsor (496)
- ARTG (489)
- Australian Public Assessment Report (AusPAR) (66)
- Prescription medicine registration (43)
- Section 14, TGO91 consent (21)
- Prescription medicine decision summary (19)
- Designation or determination (9)
- Cancellation or suspension (7)
- Prescription medicine evaluation (1)
- 2025 (13)
- 2024 (87)
- 2023 (73)
- 2022 (61)
- 2021 (126)
- 2020 (107)
- 2019 (98)
- 2018 (97)
- 2017 (73)
- 2016 (12)
- 2015 (22)
- 2014 (23)
- 2013 (9)
- 2012 (9)
- 2011 (14)
- 2010 (29)
- 2009 (13)
- 2008 (6)
- 2007 (11)
- 2006 (8)
- 2005 (4)
- 2004 (8)
- 2003 (9)
- 2002 (12)
- 2001 (8)
- 2000 (22)
- 1999 (9)
- 1998 (12)
- 1997 (18)
- 1996 (8)
- 1995 (3)
- 1994 (33)
- 1993 (19)
- 1992 (8)
- 1991 (87)
Sponsor content
1151 result(s) found, displaying 71 to 80
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Prescription medicine decision summaryCibinqo (abrocitinib) has been approved for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Jul-2024Prescription medicine evaluationActive ingredient: isavuconazonium sulfate.
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Prescription medicine decision summaryVelsipity (etrasimod) treats moderately to severely active ulcerative colitis (inflammation and ulcers in the digestive tract).